{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"TMA: Meera Sridharan, M.D., Ph.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/8b3e6ff7\"></iframe>","width":"100%","height":180,"duration":633,"description":"Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Laboratories' approach to testing for atypical hemolytic uremic syndrome (aHUS), a type of thrombotic microangiopathy (TMA) caused by the abnormal activation of the complement cascade. The serological profile examines nine analytes for a comprehensive understanding of the three different complement cascade pathways. This allows physicians to exclude other possible complement abnormalities and isolate the specific pathway problem in support of a clinical diagnosis, which has approved therapies.  ","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}